Gefitinib for oesophageal cancer: A cog in need of a wheel?

The Lancet Oncology

Volumn 15, Issue 8, 2014, Pages 790-791

  Ford, Hugo E R ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PLACEBO; VASCULOTROPIN RECEPTOR 2;

BRAF GENE; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGUS CANCER; EXON; GENE AMPLIFICATION; GENE MUTATION; HUMAN; NOTE; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PHENOTYPE; PIK3CA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TP53 GENE; TREATMENT DURATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; QUINAZOLINES;

EID: 84903545241     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70271-2     Document Type: Note

References (12)

1. Cancer stats Cancer Research UK, (accessed May 29, 2014). http://www.cancerresearchuk.org/cancer-info/cancerstats/types/oesophagus/survival/#five.
2. Devesa S, Blot WY, Fraumeni JF Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83:2049-2053.
3. Ford HER, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014, 15:78-86. on behalf of the COUGAR-02 Investigators.
4. Dutton SJ, Ferry DR, Blazeby JM, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol 2014, published online June 18. http://dx.doi.org/10.1016/S1470-2045(14)70024-5.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
6. Petrelli F, Borgonovo K, Cabbidu M, Barni S Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012, 13:107-114.
7. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
8. Lin DC, Hao JJ, Nagata Y, et al. Genomic and molecular characterisation of esophageal squamous cell carcinoma. Nat Genet 2014, 46:467-473.
9. Dulak AM, Stojanov P, Peng S, et al. Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013, 45:478-486.
10. Agrawal N, Jiao Y, Bettegowda C, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012, 2:899-905.
11. Wilke HJ, van Cutsem E, Oh SC, et al. RAINBOW: a global phase III randomized double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum and fluoropyrimidine containing chemotherapy rainbow IMCL CP 12-0922 (I4-IE-JVBE). Proc Am Soc Clin Oncol 2014, 32(supp 3). abstr LBA7.
12. Thallinger CMR, Raderer M, Hejna M Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol 2011, 29:4709-4714.